Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Faye Vazvaei

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Cancer Chemotherapy and Pharmacology|May 8, 2019
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [<sup>14</sup>C]-labeled idasanutlin and an intravenous tracer dose of [<sup>13</sup>C]-labeled idasanutlin in a single cohort of patients with solid tumorsZsuzsanna Pápai, Lin-Chi Chen, Daniel Da Costa, et al.
Bioanalysis|January 8, 2026
Streamlined neutralizing antibody assay development: overcoming serum interference, utilization of DOE and automationKelly Ngoc Pham, Nazneen Bano, Leonard J Rubinstein, et al.
Analytical Chemistry|November 6, 2020
Toward Accurate and Robust Liquid Chromatography-Mass Spectrometry-Based Quantification of Antibody Biotherapeutics in TissuesBo An, Ming Zhang, Jie Pu, et al.
The AAPS Journal|May 5, 2022
Is Incurred Sample Reanalysis (ISR) Applicable in Biomarker Assays?Amanda Hays, Lakshmi Amaravadi, Carmen Fernandez-Metzler, et al.
Cancer Chemotherapy and Pharmacology|January 26, 2018
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumorsJohn Nemunaitis, Annie Young, Samuel Ejadi, et al.
Bioanalysis|July 11, 2020
Clinical application of volumetric absorptive microsampling to the gefapixant development programBrad Roadcap, Azher Hussain, Dan Dreyer, et al.
Journal of Clinical Pharmacology|July 28, 2018
Effect of Hepatic Impairment on the Pharmacokinetics of AlectinibPeter N Morcos, Yumi Cleary, Carolina Sturm-Pellanda, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 21, 2015
Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humansKelli J Glenn, Li J Yu, Micaela B Reddy, et al.
The AAPS Journal|August 20, 2014
Repeat analysis and incurred sample reanalysis: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization teamEric Fluhler, Faye Vazvaei, Puran Singhal, et al.
The AAPS Journal|May 9, 2022
Biomarker Assay Validation by Mass SpectrometryCarmen Fernández-Metzler, Brad Ackermann, Fabio Garofolo, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Cancer Chemotherapy and Pharmacology|May 8, 2019
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [<sup>14</sup>C]-labeled idasanutlin and an intravenous tracer dose of [<sup>13</sup>C]-labeled idasanutlin in a single cohort of patients with solid tumorsZsuzsanna Pápai, Lin-Chi Chen, Daniel Da Costa, et al.
Bioanalysis|January 8, 2026
Streamlined neutralizing antibody assay development: overcoming serum interference, utilization of DOE and automationKelly Ngoc Pham, Nazneen Bano, Leonard J Rubinstein, et al.
Analytical Chemistry|November 6, 2020
Toward Accurate and Robust Liquid Chromatography-Mass Spectrometry-Based Quantification of Antibody Biotherapeutics in TissuesBo An, Ming Zhang, Jie Pu, et al.
The AAPS Journal|May 5, 2022
Is Incurred Sample Reanalysis (ISR) Applicable in Biomarker Assays?Amanda Hays, Lakshmi Amaravadi, Carmen Fernandez-Metzler, et al.
Cancer Chemotherapy and Pharmacology|January 26, 2018
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumorsJohn Nemunaitis, Annie Young, Samuel Ejadi, et al.
Bioanalysis|July 11, 2020
Clinical application of volumetric absorptive microsampling to the gefapixant development programBrad Roadcap, Azher Hussain, Dan Dreyer, et al.
Journal of Clinical Pharmacology|July 28, 2018
Effect of Hepatic Impairment on the Pharmacokinetics of AlectinibPeter N Morcos, Yumi Cleary, Carolina Sturm-Pellanda, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 21, 2015
Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humansKelli J Glenn, Li J Yu, Micaela B Reddy, et al.
The AAPS Journal|August 20, 2014
Repeat analysis and incurred sample reanalysis: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization teamEric Fluhler, Faye Vazvaei, Puran Singhal, et al.
The AAPS Journal|May 9, 2022
Biomarker Assay Validation by Mass SpectrometryCarmen Fernández-Metzler, Brad Ackermann, Fabio Garofolo, et al.
Pageof 3